Supplying Octapharma with proprietary resin for treated plasma product
LAVAL, Que.—ProMetic Life Sciences Inc. has received a $4.8-million purchase order from Octapharma under a supply agreement between the two companies.
ProMetic of Laval, Que., is supplying the Swiss company with a proprietary resin that will be incorporated into Octapharma’s manufacturing process.
The Montreal-area company is a biotechnology developer specializing on the extraction and purification of therapeutic proteins from human plasma.
Octapharma has placed an order for PrioClear to be used to manufacturer Octaplas—a treated plasma product approved for marketing in the United States and several European countries.
“This new purchase order confirms our growth forecast for shipments to Octapharma,” said Pierre Laurin, ProMetic’s president and chief executive officer.
“We anticipate further growth in the coming years as they continue to gain market share in more mature markets and grow their sales in newer markets.”